Featured Research

from universities, journals, and other organizations

Possible clues to tamoxifen resistance in breast cancer patients

Date:
March 30, 2011
Source:
Journal of the National Cancer Institute
Summary:
Breast cancer patients who become resistant to tamoxifen may have low levels of a protein called Rho GDI-alpha, according to a new study.

Breast cancer patients who become resistant to tamoxifen may have low levels of a protein called Rho GDI-alpha, according to a study published online March 30 in the Journal of the National Cancer Institute.

Women whose tumors have estrogen receptors (ERs) often take tamoxifen after surgery to prevent recurrence of the cancer and keep it from metastasizing to other parts of the body. Some patients, however, become resistant to the drug even though their tumors remain ER-positive.

To explore the mechanisms of this resistance, Suzanne Fuqua, Ph.D., professor of medicine in the Lester and Sue Smith Breast Center at Baylor College of Medicine in Houston and colleagues compared two groups of ER-positive tumors: four primary tumors from women who took tamoxifen and did not have a recurrence and five metastatic tumors from women taking tamoxifen whose tumors spread while they were on the drug. The authors found that Rho GDI-alpha was under-expressed -- its levels were low -- in the women with tamoxifen-resistant metastatic disease. They validated the association of low Rho GDI-alpha with tamoxifen resistance in laboratory cells, in human tumors implanted in mice, and in genetic data from 250 women whose ER-positive breast tumors were treated with tamoxifen.

They also found that levels another protein -- MTA2--rose markedly when Rho GD1-alpha dropped and that levels of MTA2 and Rho GDI-alpha combined predicted recurrence.

"These are the first data suggesting a tight, clinically important connection between the two pathways, Rho GDI-alpha and MTA2," the authors write. "Our data also suggest a possible mechanism, in which the loss of Rho GDI-alpha function promotes distant progression of breast tumors by triggering downstream molecules, such as MTA2, with metastasis-promoting activities."

In an accompanying editorial, Matthew J. Ellis, Ph.D. and Brian A. Van Tine, M.D. of Washington University in St. Louis note that other studies have found the proteins to be associated in various ways with breast cancer. But not all these previous findings are consistent with the findings of this study. "Thus, the status of Rho GDI-alpha as a marker of tamoxifen resistance is unclear," they write.

The editorialists also comment on the increasing number of genetic alterations emerging in breast cancer. "In the next several years," they write, "many entire breast cancer genomes will be published, revealing for the first time the enormous scale of the disruption of the human genome associated with the development of this disease." After that, they say, efforts to understand the functions of disrupted genes "will be essential for the next surge of progress."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. I. Barone, L. Brusco, G. Gu, J. Selever, A. Beyer, K. R. Covington, A. Tsimelzon, T. Wang, S. G. Hilsenbeck, G. C. Chamness, S. Ando, S. A. W. Fuqua. Loss of Rho GDI and Resistance to Tamoxifen via Effects on Estrogen Receptor . JNCI Journal of the National Cancer Institute, 2011; DOI: 10.1093/jnci/djr058

Cite This Page:

Journal of the National Cancer Institute. "Possible clues to tamoxifen resistance in breast cancer patients." ScienceDaily. ScienceDaily, 30 March 2011. <www.sciencedaily.com/releases/2011/03/110330192204.htm>.
Journal of the National Cancer Institute. (2011, March 30). Possible clues to tamoxifen resistance in breast cancer patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/03/110330192204.htm
Journal of the National Cancer Institute. "Possible clues to tamoxifen resistance in breast cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/03/110330192204.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins